Patricia L. Allen brings over 20 years of financial and operations leadership experience at both publicly traded and private biotechnology companies.
Most recently, Ms. Allen was Chief Financial Officer of Zafgen, Inc., a publicly traded biotechnology company, from January 2013 until 2020. From 2011 to 2012, she provided independent consulting services to biotechnology companies in a variety of areas, including interim chief financial officer services, fundraising, deal structures, financial planning, organizational structure, investor relations and business development. Previously, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly traded biotechnology company. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly traded biotechnology company, most recently as the Director of Finance. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen graduated summa cum laude from Bryant College with a B.S. in business administration. She currently serves as a member of the Board of Directors at multiple publicly traded and privately held companies including Deciphera Pharmaceuticals, Inc. and Yumanity Therapeutics, Inc. where she also serves as the Chair of the Audit Committee.